Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Next Previous
Trial Profile

NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs ALT 803 (Primary) ; CST 101 (Primary) ; ETBX 011 (Primary) ; GI 4000 (Primary) ; Avelumab; Bevacizumab; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NantCell; NantKwest

    • Most Recent Events

    • 04 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 23 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 09 May 2017 According to a NantKwest media release, U.S. Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) Application for enrollment to this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top